;PMID: 10968705
;source_file_2865.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..111] = [t:50..111]
;2)section:[e:115..123] = [t:115..123]
;3)section:[e:127..241] = [t:127..241]
;4)sentence:[e:245..546] = [t:245..546]
;5)sentence:[e:547..719] = [t:547..719]
;6)sentence:[e:720..978] = [t:720..978]
;7)sentence:[e:979..1176] = [t:979..1176]
;8)sentence:[e:1177..1269] = [t:1177..1269]
;9)section:[e:1273..1291] = [t:1273..1291]
;10)section:[e:1297..1303] = [t:1297..1303]
;11)section:[e:1309..1325] = [t:1309..1325]
;12)section:[e:1329..1374] = [t:1329..1374]

;section 0 Span:0..44
;Semin Diagn Pathol.  2000 Aug;17(3):194-203.
(SEC
  (FRAG (NNP:[0..5] Semin) (NNP:[6..11] Diagn) (NNP:[12..18] Pathol)
        (.:[18..19] .) (CD:[21..25] 2000) (CC:[26..33] Aug;17-LRB-)
        (CD:[33..34] 3) (-RRB-:[34..35] -RRB-) (CD:[35..39] :194)
        (CD:[39..43] -203) (.:[43..44] .)))

;sentence 1 Span:50..111
;Immunohistology of neuroendocrine and neuroectodermal tumors.
;[69..83]...[104..110]:malignancy-type:"neuroendocrine"..."tumors"
;[88..110]:malignancy-type:"neuroectodermal tumors"
(SENT
  (NP-HLN
    (NP (NN:[50..65] Immunohistology))
    (PP (IN:[66..68] of)
      (NP
        (NP (JJ:[69..83] neuroendocrine)
          (NML-1 (-NONE-:[83..83] *P*)))
        (CC:[84..87] and)
        (NP (JJ:[88..103] neuroectodermal)
          (NML-1 (NNS:[104..110] tumors)))))
    (.:[110..111] .)))

;section 2 Span:115..123
;Wick MR.
(SEC
  (FRAG (NNP:[115..119] Wick) (NNP:[120..123] MR.)))

;section 3 Span:127..241
;Fechner Laboratory of Surgical Pathology, University of Virginia Medical
;Center,  Charlottesville 22908-0214, USA.
(SEC
  (FRAG (NNP:[127..134] Fechner) (NNP:[135..145] Laboratory) (IN:[146..148] of)
        (NNP:[149..157] Surgical) (NNP:[158..167] Pathology) (,:[167..168] ,)
        (NNP:[169..179] University) (IN:[180..182] of) (NNP:[183..191] Virginia)
        (NNP:[192..199] Medical) (NNP:[200..206] Center) (,:[206..207] ,)
        (NNP:[209..224] Charlottesville) (CD:[225..229] 2290) (CD:[229..230] 8)
        (CD:[230..235] -0214) (,:[235..236] ,) (NNP:[237..240] USA)
        (.:[240..241] .)))

;sentence 4 Span:245..546
;Neuroendocrine and neuroectodermal tumors are interrelated, and comprise a 
;neoplastic family including lesions formerly termed "carcinoid," "atypical 
;carcinoid," "small cell undifferentiated carcinoma," "primitive 
;neuroepithelioma," "chemodectoma," and "neuroblastoma," to name but a few 
;entities.
;[245..259]...[280..286]:malignancy-type:"Neuroendocrine"..."tumors"
;[264..286]:malignancy-type:"neuroectodermal tumors"
;[321..331]:malignancy-type:"neoplastic"
;[349..356]:malignancy-type:"lesions"
;[374..383]:malignancy-type:"carcinoid"
;[387..406]:malignancy-type:"atypical  carcinoid"
;[410..447]:malignancy-type:"small cell undifferentiated carcinoma"
;[451..460]:malignancy-clinical-stage:"primitive"
;[462..478]:malignancy-type:"neuroepithelioma"
;[482..494]:malignancy-type:"chemodectoma"
;[502..515]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ-2
      (NP (JJ:[245..259] Neuroendocrine)
        (NML-1 (-NONE-:[259..259] *P*)))
      (CC:[260..263] and)
      (NP (JJ:[264..279] neuroectodermal)
        (NML-1 (NNS:[280..286] tumors))))
    (VP
      (VP (VBP:[287..290] are)
        (VP (VBN:[291..303] interrelated)
          (NP-2 (-NONE-:[303..303] *))))
      (,:[303..304] ,) (CC:[305..308] and)
      (VP (VBP:[309..317] comprise)
        (NP
          (NP (DT:[318..319] a) (JJ:[321..331] neoplastic)
              (NN:[332..338] family))
          (PP (VBG:[339..348] including)
            (NP
              (NP (NNS:[349..356] lesions))
              (VP
                (ADVP (RB:[357..365] formerly))
                (VBN:[366..372] termed)
                (NP (-NONE-:[372..372] *))
                (UCP (``:[373..374] ")
                  (NP (JJ:[374..383] carcinoid))
                  (,:[383..384] ,) ('':[384..385] ") (``:[386..387] ")
                  (ADJP (JJ:[387..395] atypical) (JJ:[397..406] carcinoid))
                  (,:[406..407] ,) ('':[407..408] ") (``:[409..410] ")
                  (NP
                    (NML (JJ:[410..415] small) (NN:[416..420] cell))
                    (JJ:[421..437] undifferentiated) (NN:[438..447] carcinoma))
                  (,:[447..448] ,) ('':[448..449] ") (``:[450..451] ")
                  (NP (JJ:[451..460] primitive) (NN:[462..478] neuroepithelioma))
                  (,:[478..479] ,) ('':[479..480] ") (``:[481..482] ")
                  (NP (NN:[482..494] chemodectoma))
                  (,:[494..495] ,) ('':[495..496] ") (CC:[497..500] and)
                   (``:[501..502] ")
                  (NP (NN:[502..515] neuroblastoma)))))))
        (,:[515..516] ,) ('':[516..517] ")
        (S-ADV
          (NP-SBJ (-NONE-:[517..517] *))
          (VP (TO:[518..520] to)
            (VP (VB:[521..525] name)
              (NP (RB:[526..529] but) (DT:[530..531] a) (JJ:[532..535] few)
                  (NNS:[537..545] entities)))))))
    (.:[545..546] .)))

;sentence 5 Span:547..719
;The nosology of these neoplasms has been simplified recently, in part  as a
;result of a better understanding of their immunophenotypes and molecular 
;biological attributes.
;[569..578]:malignancy-type:"neoplasms"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[547..550] The) (NN:[551..559] nosology))
      (PP (IN:[560..562] of)
        (NP (DT:[563..568] these) (NNS:[569..578] neoplasms))))
    (VP (VBZ:[579..582] has)
      (VP (VBN:[583..587] been)
        (VP (VBN:[588..598] simplified)
          (NP-1 (-NONE-:[598..598] *))
          (ADVP-TMP (RB:[599..607] recently))
          (,:[607..608] ,)
          (PP
            (PP (IN:[609..611] in)
              (NP (NN:[612..616] part)))
            (IN:[618..620] as)
            (NP
              (NP (DT:[621..622] a) (NN:[623..629] result))
              (PP (IN:[630..632] of)
                (NP
                  (NP (DT:[633..634] a) (JJR:[635..641] better)
                      (NN:[642..655] understanding))
                  (PP (IN:[656..658] of)
                    (NP
                      (NP (PRP$:[659..664] their)
                          (NNS:[665..681] immunophenotypes))
                      (CC:[682..685] and)
                      (NP (JJ:[686..695] molecular) (JJ:[697..707] biological)
                          (NNS:[708..718] attributes)))))))))))
    (.:[718..719] .)))

;sentence 6 Span:720..978
;This review considers those immunohistochemical markers  that are now
;generally available for diagnostic evaluation of neuroendocrine and 
;neuroectodermal differentiation, and provides information on the relative 
;sensitivity and specificity of each of them.
(SENT
  (S
    (NP-SBJ (DT:[720..724] This) (NN:[725..731] review))
    (VP
      (VP (VBZ:[732..741] considers)
        (NP
          (NP (DT:[742..747] those) (JJ:[748..767] immunohistochemical)
              (NNS:[768..775] markers))
          (SBAR
            (WHNP-1 (WDT:[777..781] that))
            (S
              (NP-SBJ-1 (-NONE-:[781..781] *T*))
              (VP (VBP:[782..785] are)
                (ADVP-TMP (RB:[786..789] now))
                (ADJP-PRD (RB:[790..799] generally) (JJ:[800..809] available)
                  (PP (IN:[810..813] for)
                    (NP
                      (NP (JJ:[814..824] diagnostic) (NN:[825..835] evaluation))
                      (PP (IN:[836..838] of)
                        (NP
                          (NP (JJ:[839..853] neuroendocrine)
                            (NML-2 (-NONE-:[853..853] *P*)))
                          (CC:[854..857] and)
                          (NP (JJ:[859..874] neuroectodermal)
                            (NML-2 (NN:[875..890] differentiation)))))))))))))
      (,:[890..891] ,) (CC:[892..895] and)
      (VP (VBZ:[896..904] provides)
        (NP
          (NP (NN:[905..916] information))
          (PP (IN:[917..919] on)
            (NP
              (NP (DT:[920..923] the) (JJ:[924..932] relative)
                (NML (NN:[934..945] sensitivity) (CC:[946..949] and)
                     (NN:[950..961] specificity)))
              (PP (IN:[962..964] of)
                (NP
                  (NP (DT:[965..969] each))
                  (PP (IN:[970..972] of)
                    (NP (PRP:[973..977] them))))))))))
    (.:[977..978] .)))

;sentence 7 Span:979..1176
;Intermediate filament proteins,  chromogranins, synaptophysin, CD56, CD57,
;CD99, neuron-specific (gamma-dimer)  enolase, protein gene product 9.5, and
;specific neuropeptide products are  discussed.
;[979..1009]:gene-protein:"Intermediate filament proteins"
;[1012..1025]:gene-protein:"chromogranins"
;[1027..1040]:gene-protein:"synaptophysin"
;[1042..1046]:gene-protein:"CD56"
;[1048..1052]:gene-protein:"CD57"
;[1054..1058]:gene-protein:"CD99"
;[1060..1098]:gene-protein:"neuron-specific (gamma-dimer)  enolase"
;[1108..1124]:gene-protein:"gene product 9.5"
;[1139..1151]:gene-protein:"neuropeptide"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[979..991] Intermediate) (NN:[992..1000] filament)
          (NNS:[1001..1009] proteins))
      (,:[1009..1010] ,)
      (NP (NNS:[1012..1025] chromogranins))
      (,:[1025..1026] ,)
      (NP (NN:[1027..1040] synaptophysin))
      (,:[1040..1041] ,)
      (NP (NN:[1042..1046] CD56))
      (,:[1046..1047] ,)
      (NP (NN:[1048..1052] CD57))
      (,:[1052..1053] ,)
      (NP (NN:[1054..1058] CD99))
      (,:[1058..1059] ,)
      (NP
        (NML (NN:[1060..1066] neuron) (HYPH:[1066..1067] -)
             (JJ:[1067..1075] specific))
        (PRN (-LRB-:[1076..1077] -LRB-)
          (NP (NN:[1077..1088] gamma-dimer))
          (-RRB-:[1088..1089] -RRB-))
        (NN:[1091..1098] enolase))
      (,:[1098..1099] ,)
      (NP (NN:[1100..1107] protein)
         (NN:[1108..1112] gene) (NN:[1113..1120] product) (CD:[1121..1124] 9.5))
      (,:[1124..1125] ,) (CC:[1126..1129] and)
      (NP (JJ:[1130..1138] specific) (NN:[1139..1151] neuropeptide)
          (NNS:[1152..1160] products)))
    (VP (VBP:[1161..1164] are)
      (VP (VBN:[1166..1175] discussed)
        (NP-1 (-NONE-:[1175..1175] *))))
    (.:[1175..1176] .)))

;sentence 8 Span:1177..1269
;The application of such determinants in regional differential  diagnosis is
;also summarized.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1177..1180] The) (NN:[1181..1192] application))
      (PP (IN:[1193..1195] of)
        (NP (JJ:[1196..1200] such) (NNS:[1201..1213] determinants)))
      (PP (IN:[1214..1216] in)
        (NP (JJ:[1217..1225] regional) (JJ:[1226..1238] differential)
            (NN:[1240..1249] diagnosis))))
    (VP (VBZ:[1250..1252] is)
      (ADVP (RB:[1253..1257] also))
      (VP (VBN:[1258..1268] summarized)
        (NP-1 (-NONE-:[1268..1268] *))))
    (.:[1268..1269] .)))

;section 9 Span:1273..1291
;Publication Types:
(SEC
  (FRAG (NNP:[1273..1284] Publication) (NNP:[1285..1290] Types)
        (::[1290..1291] :)))

;section 10 Span:1297..1303
;Review
(SEC
  (FRAG (NNP:[1297..1303] Review)))

;section 11 Span:1309..1325
;Review, Academic
(SEC
  (FRAG (NNP:[1309..1315] Review) (,:[1315..1316] ,) (NNP:[1317..1325] Academic)))

;section 12 Span:1329..1374
;PMID: 10968705 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1329..1333] PMID) (::[1333..1334] :) (CD:[1335..1343] 10968705)
        (NN:[1344..1345] -LSB-) (NNP:[1345..1351] PubMed) (::[1352..1353] -)
        (NN:[1354..1361] indexed) (IN:[1362..1365] for)
        (NNP:[1366..1374] MEDLINE-RSB-)))
